Background pattern
LONQUEX 6 mg/0.6 mL Injectable Solution

LONQUEX 6 mg/0.6 mL Injectable Solution

Ask a doctor about a prescription for LONQUEX 6 mg/0.6 mL Injectable Solution

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use LONQUEX 6 mg/0.6 mL Injectable Solution

Introduction

Package Leaflet: Information for the Patient

Lonquex 6 mg/0.6 ml Solution for Injection

lipegfilgrastim

Read all of this leaflet carefully before you start receiving this medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor, pharmacist or nurse.
  • If you experience any side effects, talk to your doctor, pharmacist or nurse, even if they are not listed in this leaflet. See section 4.

Contents of the Package Leaflet

  1. What is Lonquex and what is it used for
  2. What you need to know before you receive Lonquex
  3. How Lonquex is administered
  4. Possible side effects
  5. Storage of Lonquex
  6. Contents of the pack and further information

1. What is Lonquex and what is it used for

What is Lonquex

Escherichia coli.

It belongs to a group of proteins called cytokines and is similar to a natural protein (granulocyte-colony stimulating factor [G-CSF]) produced by your own body.

What Lonquex is used for

Your doctor has prescribed Lonquex to you or your child to reduce the duration of a condition called neutropenia (low white blood cell count) and the occurrence of febrile neutropenia (low white blood cell count with fever). These problems can be caused by the use of cytotoxic chemotherapy (medicines that destroy rapidly growing cells).

How Lonquex works

2. What you need to know before you receive Lonquex

Do not use Lonquex:

  • if you or your child is allergic to lipegfilgrastim or to any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Talk to your doctor, pharmacist or nurse before starting Lonquex.

  • if you or your child notices pain in the upper left side of the abdomen or in the tip of the shoulder. This could be due to a spleen disorder (see section 4 “Possible side effects”).
  • if you or your child has a cough, fever, and difficulty breathing. This could be due to a lung disorder (see section 4 “Possible side effects”).
  • if you or your child has sickle cell anaemia or other conditions where the red blood cells are abnormal.
  • if you or your child has previously experienced allergic reactions to other medicines similar to this one (e.g. filgrastim, lenograstim or pegfilgrastim from the G-CSF group). You may also be at risk of a reaction to Lonquex.

Your doctor will perform regular blood tests to monitor various components of your blood and their concentrations. Your doctor will also periodically check your urine or your child's urine, as other medicines similar to this one (e.g. other granulocyte-colony stimulating factors such as filgrastim, lenograstim or pegfilgrastim) may damage the small filters in the kidneys (glomerulonephritis; see section 4 “Possible side effects”).

Rarely, inflammation of the aorta (the large blood vessel that carries blood from the heart to the rest of the body) has been reported with other medicines like this one (e.g. filgrastim, lenograstim or pegfilgrastim from the G-CSF group). Symptoms may include fever, abdominal pain, general malaise, back pain, and increased inflammatory markers. Tell your doctor if you experience these symptoms.

Children and adolescents

Other medicines and Lonquex

Tell your doctor or pharmacist if you or your child is using, has recently used or might use any other medicines.

Pregnancy and breastfeeding

It is not known whether the active substance of this medicine passes into breast milk. Therefore, you should stop breastfeeding during treatment.

Driving and using machines

The influence of Lonquex on your ability to drive and use machines is negligible or nil.

This medicine contains 30 mg of sorbitol in each vial.

This medicine contains less than 1 mmol of sodium (23 mg) per vial, i.e. it is essentially “sodium-free”.

3. How Lonquex is administered

What is the recommended dose

The recommended dose in adults is 6 mg (one 0.6 ml vial) once per chemotherapy cycle.

The recommended dose in children and adolescents is based on their body weight:

Body weight (kg)

Dose (once per chemotherapy cycle)

< 10

0.6 mg (0.06 ml)

≥ 10 to < 20

1.5 mg (0.15 ml)

≥ 20 to < 30

2.5 mg (0.25 ml)

≥ 30 to < 45

4.0 mg (0.40 ml)

≥ 45

6.0 mg (0.60 ml)

When will Lonquex be administered

The dose of Lonquex will usually be injected approximately 24 hours after the last dose of chemotherapy, at the end of each chemotherapy cycle.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

More serious side effects

  • Rarely (may affect up to 1 in 100 people), allergic reactions such as skin rash, raised and itchy patches on the skin, and severe allergic reactions with weakness, low blood pressure, difficulty breathing, and swelling of the face have been reported. If you think you are experiencing this type of reaction, you must stop the injection of Lonquex and seek medical help immediately.
  • Rarely, cases of enlarged spleen and spleen rupture have been reported with other medicines similar to Lonquex. Some cases of spleen rupture were fatal. It is important that you contact your doctor immediately if you notice pain in the upper left side of the abdomen or in the left shoulder, as these symptoms may be related to a problem with the spleen.
  • Cough, fever, and difficulty or pain when breathing may be signs of serious lung side effects, such as pneumonia and acute respiratory distress syndrome, which can be fatal. If you experience fever or any of these symptoms, it is important that you contact your doctor immediately.
  • Contact your doctor immediately if you experience any of the following symptoms: swelling that may be associated with urinating less often, difficulty breathing, swelling, and feeling of fullness in the abdomen, and a general feeling of tiredness. These symptoms usually develop very quickly.

These may be symptoms of a condition called “capillary leak syndrome”, which causes blood to leak from small blood vessels in your body and requires urgent medical attention.

Other side effects

Very common (may affect more than 1 in 10 people)

  • Musculoskeletal pain, such as bone pain, joint pain, muscle pain, limb pain, chest pain, neck pain, or back pain. Tell your doctor if you experience severe musculoskeletal pain.
  • Nausea.

Common (may affect up to 1 in 10 people)

  • Decreased platelet count, which increases the risk of bleeding or bruising.
  • Headache.
  • Skin reactions, such as redness or rash.
  • Low potassium levels in the blood, which can cause muscle weakness, twitching, or heart rhythm disturbances.
  • Chest pain.
  • Bloody cough.

Uncommon (may affect up to 1 in 100 people)

  • Increased white blood cell count.
  • Local reactions at the injection site, such as pain or hardening.
  • Some changes in blood tests may occur, but these will be detected in routine blood tests.
  • Bleeding in the lung.

Frequency not known (cannot be estimated from the available data)

  • Inflammation of the aorta (the large blood vessel that carries blood from the heart to the rest of the body), see section 2.

Side effects that have been seen with similar medicines, but not yet with Lonquex

  • Sickle cell crisis in patients with sickle cell anaemia.
  • Painful red-purple skin lesions on the limbs, and sometimes on the face and neck, accompanied by fever (Sweet's syndrome).
  • Inflammation of the blood vessels in the skin.
  • Damage to the small filters in the kidneys (glomerulonephritis; see section 2 under the heading “Warnings and precautions”).

Reporting of side effects

If you experience any side effects, talk to your doctor, pharmacist or nurse, even if they are not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Lonquex

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the outer packaging and on the label of the vial after EXP. The expiry date is the last day of the month shown.

Store in a refrigerator (2 °C – 8 °C).

Do not freeze.

Keep the vial in the outer packaging to protect it from light.

Do not use this medicine if it is cloudy or contains particles.

6. Contents of the pack and further information

Composition of Lonquex

  • The active substance is lipegfilgrastim. Each ml of solution contains 10 mg of lipegfilgrastim. Each 0.6 ml vial contains 6 mg of lipegfilgrastim.
  • The other ingredients (excipients) are glacial acetic acid, sodium hydroxide, sorbitol (E420), polysorbate 20, and water for injections.

Appearance and packaging of the product

Not all pack sizes may be marketed.

Marketing authorisation holder

Teva B.V.

Swensweg 5

2031 GA Haarlem

Netherlands

Manufacturer

Teva Biotech GmbH

Dornierstraße 10

89079 Ulm

Germany

Merckle GmbH

Graf-Arco-Straße 3

89079 Ulm

Germany

You can get more information about this medicine from your local representative of the marketing authorisation holder:

België/Belgique/Belgien

Teva Pharma Belgium N.V./S.A./AG

Tel: +32 38207373

Lietuva

UAB Teva Baltics

Tel: +370 52660203

Text in Bulgarian language with the name of the company Teva Pharma EAD and phone number +359 24899585

Luxembourg/Luxemburg

Teva Pharma Belgium N.V./S.A./AG

Belgique/Belgien

Tel: +32 38207373

Česká republika

Teva Pharmaceuticals CR, s.r.o.

Tel: +420 251007111

Magyarország

Teva Gyógyszergyár Zrt.

Tel: +36 12886400

Danmark

Teva Denmark A/S

Tlf: +45 44985511

Malta

Teva Pharmaceuticals Ireland

Ireland

Tel: +44 2075407117

Deutschland

TEVA GmbH

Tel: +49 73140208

Nederland

Teva Nederland B.V.

Tel: +31 8000228400

Eesti

UAB Teva Baltics Eesti filiaal

Tel: +372 6610801

Norge

Teva Norway AS

Tlf: +47 66775590

Ελλάδα

Specifar A.B.E.E.

Τηλ: +30 2118805000

Österreich

ratiopharm Arzneimittel Vertriebs-GmbH

Tel: +43 1970070

España

Teva Pharma, S.L.U.

Tel: +34 913873280

Polska

Teva Pharmaceuticals Polska Sp. z o.o.

Tel: +48 223459300

France

Teva Santé

Tél: +33 155917800

Portugal

Teva Pharma - Produtos Farmacêuticos, Lda.

Tel: +351 214767550

Hrvatska

Pliva Hrvatska d.o.o.

Tel: +385 13720000

România

Teva Pharmaceuticals S.R.L.

Tel: +40 212306524

Ireland

Teva Pharmaceuticals Ireland

Tel: +44 2075407117

Slovenija

Pliva Ljubljana d.o.o.

Tel: +386 15890390

Ísland

Alvogen ehf.

Sími: +354 5222900

Slovenská republika

TEVA Pharmaceuticals Slovakia s.r.o.

Tel: +421 257267911

Italia

Teva Italia S.r.l.

Tel: +39 028917981

Suomi/Finland

Teva Finland Oy

Puh/Tel: +358 201805900

Κύπρος

Specifar A.B.E.E.

Ελλάδα

Τηλ: +30 2118805000

Sverige

Teva Sweden AB

Tel: +46 42121100

Latvija

UAB Teva Baltics filiale Latvija

Tel: +371 67323666

United Kingdom (Northern Ireland)

Teva Pharmaceuticals Ireland

Ireland

Tel: +44 2075407117

Date of last revision of this leaflet: {month YYYY}

Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.

This information is intended only for healthcare professionals or medical staff:

Storage and inspection

Store in a refrigerator (2 °C – 8 °C). Do not freeze. Keep the vial in the outer packaging to protect it from light.

The solution should be allowed to reach a comfortable temperature (15°C – 25°C) for injection.

Once removed from the refrigerator, Lonquex can be stored below 25 °C for a single period of up to 7 days.

The solution must be inspected visually before use. Only clear and colourless solutions without particles should be used.

Vigorous shaking should be avoided. Excessive shaking may cause the lipegfilgrastim to aggregate, making it biologically inactive.

Method of administration

The recommended dose should be injected subcutaneously (SC) using a suitable syringe with the appropriate graduation for the prescribed dose.

The injection should be administered in the abdomen, upper arm, or thigh.

Procedure for proper disposal

Disposal of unused medicine and all materials that have come into contact with it should be done according to local regulations.

Get updates and exclusive offers

Be the first to know about new services, marketplace updates, and subscriber-only promos.

Follow us on social media
FacebookInstagram
Logo
Oladoctor
Find a doctor
Doctors by specialty
Services
Choose language
© 2025 Oladoctor. All rights reserved.
VisaMastercardStripe